CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,684 enrolled
Drug / intervention
Potassiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04053816
NCT04053816Phase 3Completed

The TIGHT-K STUDY. Prevention of Dysrhythmias on the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter

Barts & The London NHS Trust·interventional·Posted Aug 13, 2019·Updated Nov 5, 2024

In Brief

A Phase 3 clinical trial evaluating Potassium for Arrhythmias, Cardiac. Completed, enrolled 1,684 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a strategy of maintaining serum potassium levels at ≥3.6 mEq/L is non-inferior to a strategy of usual treatment (≥4.5 mEq/L) on the occurrence of new onset atrial fibrillation after cardiac surgery (AFACS) in patients undergoing isolated coronary artery bypass graft (CABG) surgery.

Study Details

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 13, 2019
Enrollment StartOct 20, 2020
Primary CompletionNov 22, 2023
Study CompletionJun 26, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.9 years ago

Interventions

Potassiumdrug

The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference. Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.